TIP harnesses ADVA for successful trial of end-to-end open optical network
ADVA (FSE: ADV) today announced that its FSP 3000 open line system (OLS) and Ensemble Controller network management and SDN domain controller system played a key role in a successful Telecom Infra Project (TIP) open optical networking proof of concept (PoC). The demo is a crucial step for vendor-neutral disaggregated solutions with operators able to mix and match best-in-breed technology and leverage different product lifecycles. The PoC showed how multi-vendor network components can be managed by a unified software-defined networking (SDN) control system. Specifically designed for easy interoperability, ADVA’s FSP 3000 OLS and Ensemble Controller ensured seamless integration into the open environment, including third-party terminals. The PoC will be on display at OFC at the virtual Demo Zone from June 7 to 11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005193/en/
ADVA’s technology played a crucial role in TIP’s open optical networking PoC (Photo: Business Wire)
“This PoC is an important milestone in the journey to fully open and disaggregated optical networking. It offers new levels of visibility and a way to manage the entire multi-vendor environment. With the power to seamlessly integrate components from different suppliers, network operators can confidently deploy best-in-class infrastructure that meets their exact requirements,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 OLS was central to the demo. It’s a truly open solution that gives operators freedom to build multi-supplier architectures and then evolve and optimize each network layer separately. With our Ensemble Controller also playing a major role – providing network management and programmatic SDN control – this demo highlights the value of technology like ours that supports interoperability and disaggregation.”
Conducted by TIP’s Converged Architectures for Network Disaggregation & Integration (CANDI) sub-group, the PoC proved that all components of an open optical network can be operated by a single SDN controller. By demonstrating unified management of the OLS, open terminals and optical planning tool, the demo paves the way for true open networking and a new model of infrastructure operations with operators taking over network integration and optimization processes. The demo utilized ADVA’s compact and modular FSP 3000 OLS. With its open interfaces, the OLS interworks seamlessly with third-party transceivers and supports the latest coherent transport innovation. It also featured ADVA’s Ensemble Controller network management system, which was specifically designed to help network operators break up network layers while moving towards a software-defined multi-vendor architecture. TIP partners collaborating with ADVA on the demo included the major network operators Orange, Telefónica and Telia Company.
“The success of TIP’s PoC offers a major boost to communication service providers looking to harness the benefits of increased agility and supplier diversity in their optical infrastructure. Our open technology gives network operators the opportunity to massively increase efficiencies by moving away from closed proprietary systems and towards vendor-neutral networking,” commented Stephan Neidlinger, VP, global business development, ADVA. “The TIP community has once again accomplished a significant step forward for open, disaggregated and standards-based connectivity technology. By collaborating closely with our partners in this project, our team has helped to accelerate the development of the next generation of communication networks, free from vendor lock-in and ready to connect tomorrow’s world.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005193/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 16:01:00 EET | Press release
Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ
Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 16:00:00 EET | Press release
Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as enterprises and AI developers alike seek a better, more predictable alternative to the hyperscalers.” Wasabi disrupted the cloud storage model in 2017 wi
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom